15 July 2020 

An interim analysis of a Phase I clinical trial assessing Moderna‘s Covid-19 vaccine candidate, mRNA-1273, has found the product to be generally safe and well-tolerated without any serious adverse events reported through to day 57. Adverse events were said to be generally transient and mild to moderate in severity.

A study by professor Yaakov Nahmias at Hebrew University in Israel has showed that an existing cholesterol medicine, called fenofibrate, could ‘downgrade’ Covid-19 threat level to that of a common cold. The findings are based on lab tests conducted on human lung cells infected with SARS-CoV-2.

AstraZeneca has partnered with IQVIA to speed-up clinical trials of its Covid-19 vaccine candidate, AZD1222. This collaboration, which is part of the US Government’s Operation Warp Speed, is intended to accelerate trials of the vaccine in the US by leveraging IQVIA’s Virtual Trial solutions.

Dosing has commenced in a Phase I clinical trial of Medicago’s plant-derived Covid-19 vaccine candidate. The trial will evaluate the safety, tolerability, and immunogenicity of the vaccine candidate at three dose levels, unadjuvanted or adjuvanted with either Dynavax‘s CpG 1018 adjuvant or GSK‘s adjuvant technology.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.